#1 Clinical Trials Search in Europe

Pacritinib

Pacritinib is an investigational drug being studied in clinical trials for the treatment of various blood disorders, particularly myelofibrosis. This article summarizes key information from several clinical trials evaluating pacritinib’s safety, efficacy, and potential uses in conditions like myelofibrosis, myelodysplastic syndromes, and other blood cancers. The trials are examining different dosing regimens and patient populations to determine the optimal use of pacritinib.

Table of Contents

Introduction

Pacritinib is an investigational drug that has shown promise in treating various blood disorders and cancers. This article will provide an overview of pacritinib, including its potential uses, how it works, and current research efforts.[1][2][3]

What is Pacritinib?

Pacritinib is an oral medication that belongs to a class of drugs called JAK inhibitors. It specifically targets two important proteins in the body: JAK2 and IRAK1. These proteins are involved in signaling pathways that can become overactive in certain blood disorders and cancers.[1]

Pacritinib is also known by its alternative name SB1518.[3]

Conditions Treated with Pacritinib

Pacritinib is being studied for the treatment of several conditions, including:

  • VEXAS syndrome: A rare autoinflammatory disorder affecting blood cells and causing various symptoms[1]
  • T-cell lymphoproliferative disorders: A group of blood cancers affecting T-cells[2]
  • Myelofibrosis: A rare bone marrow cancer that disrupts the body’s normal production of blood cells[4]
  • Prostate cancer: Specifically for patients with biochemical relapse after initial treatment[3]

How Pacritinib Works

Pacritinib works by inhibiting (blocking) the activity of certain proteins, primarily JAK2 and IRAK1. These proteins are involved in cellular signaling pathways that can become overactive in blood disorders and cancers. By inhibiting these proteins, pacritinib may help to:

  • Reduce inflammation in conditions like VEXAS syndrome[1]
  • Slow down or stop the growth of cancer cells in lymphomas and other cancers[2]
  • Improve blood cell production in myelofibrosis[4]

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of pacritinib for various conditions:

  • A Phase 1 study for VEXAS syndrome[1]
  • A Phase 2 study for relapsed/refractory T-cell lymphoproliferative disorders[2]
  • A Phase 2 study for biochemical relapse in prostate cancer[3]
  • A Phase 2 study for myelofibrosis patients before stem cell transplantation[4]

Dosage and Administration

In most clinical trials, pacritinib is administered orally as a 200 mg dose taken twice daily.[1][2][3] However, the exact dosage and duration of treatment may vary depending on the specific condition being treated and individual patient factors. Always follow the instructions provided by your healthcare provider.

Potential Side Effects

As with any medication, pacritinib may cause side effects. Common side effects reported in clinical trials include:

  • Gastrointestinal issues (e.g., nausea, diarrhea)[4]
  • Fatigue
  • Headache

It’s important to note that the full range of potential side effects is still being studied in ongoing clinical trials. Your healthcare provider will monitor you closely for any adverse reactions if you participate in a pacritinib trial.

Frequently Asked Questions

Is pacritinib approved for use?

As of now, pacritinib is still an investigational drug and is not yet approved for general use. It is only available through clinical trials or expanded access programs.

How is pacritinib different from other JAK inhibitors?

Pacritinib is unique because it specifically targets JAK2 and IRAK1, with minimal effects on JAK1. This may result in fewer side effects related to immune suppression compared to other JAK inhibitors.

Can pacritinib be used in combination with other treatments?

Some clinical trials are exploring the use of pacritinib in combination with other treatments, such as before stem cell transplantation in myelofibrosis patients. However, more research is needed to determine the safety and efficacy of combination therapies.

Summary Table

Aspect Details
Drug Name Pacritinib (SB1518)
Drug Class JAK inhibitor
Primary Targets JAK2 and IRAK1 proteins
Conditions Studied VEXAS syndrome, T-cell lymphomas, Myelofibrosis, Prostate cancer
Administration Oral, typically 200 mg twice daily
Current Status Investigational (in clinical trials)

Glossary

  • JAK inhibitor – A type of drug that blocks the action of Janus kinase enzymes, which are involved in cell signaling and growth
  • VEXAS syndrome – A rare autoinflammatory disorder caused by genetic mutations affecting blood cells
  • Myelofibrosis – A rare type of blood cancer that affects the bone marrow, leading to scarring and impaired blood cell production
  • T-cell lymphoproliferative disorders – A group of blood cancers characterized by the abnormal growth of T-cells, a type of white blood cell
  • Biochemical relapse – In prostate cancer, this refers to a rise in PSA levels after initial treatment, indicating possible cancer recurrence

Trial Sources

  • [1]: https://clinicaltrials.gov/study/NCT06538181
  • [2]: https://clinicaltrials.gov/study/NCT04858256
  • [3]: https://clinicaltrials.gov/study/NCT04635059
  • [4]: https://clinicaltrials.gov/study/NCT03645824
  • [5]: https://clinicaltrials.gov/study/NCT02803762
Aspect Details
Main Conditions Studied Myelofibrosis, Myelodysplastic Syndromes, T-cell Lymphomas, VEXAS Syndrome
Dosage Forms Oral capsules, typically 100-200 mg twice daily
Key Outcome Measures Spleen volume reduction, symptom improvement, blood count changes, overall response rate
Safety Assessments Adverse events, dose-limiting toxicities, pharmacokinetics
Patient Populations Adults, some trials including adolescents aged 12-17
Trial Phases Phase 1, Phase 2, some combined Phase 1/2
Unique Aspects Targets multiple proteins (JAK2, FLT3, IRAK1, CSF1R), potential for use in rare disorders

FAQ

  • What is pacritinib? Pacritinib is an investigational drug that inhibits several proteins in the body, including JAK2, FLT3, IRAK1, and CSF1R. It is being studied as a potential treatment for various blood disorders, especially myelofibrosis.
  • What conditions is pacritinib being studied to treat? Pacritinib is being evaluated in clinical trials for myelofibrosis, myelodysplastic syndromes, T-cell lymphomas, prostate cancer, and other blood disorders like VEXAS syndrome.
  • How is pacritinib taken? In most trials, pacritinib is taken orally as a capsule, usually twice daily. The dosage being studied ranges from 100 mg to 400 mg per day, depending on the specific trial.
  • What are some of the potential benefits of pacritinib? Clinical trials are evaluating if pacritinib can reduce spleen size, improve symptoms, and enhance blood cell counts in patients with myelofibrosis. It may also have benefits in other blood disorders by targeting specific proteins involved in disease processes.
  • What are researchers looking at to determine if pacritinib is effective? Researchers are examining factors like reduction in spleen volume, improvement in symptom scores, changes in blood cell counts, overall response rates, and quality of life measures to assess pacritinib's effectiveness in various conditions.

Ongoing Clinical Trials on Pacritinib

  • A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Czechia France Hungary Italy Poland +2

Glossary

  • Myelofibrosis: A rare blood cancer where abnormal blood cells and fibers build up in the bone marrow, leading to impaired blood cell production.
  • JAK2: A protein involved in sending signals in cells that control blood cell production. Mutations in the JAK2 gene are common in myeloproliferative neoplasms.
  • FLT3: A protein that plays a role in the growth and survival of blood cells. Mutations in the FLT3 gene are found in some blood cancers.
  • IRAK1: A protein involved in immune system signaling. It may play a role in the development of some blood disorders.
  • CSF1R: A protein that helps control the production and function of certain blood cells, particularly macrophages.
  • Spleen volume reduction: A decrease in the size of the spleen, which is often enlarged in myelofibrosis. This is a key measure of treatment effectiveness.
  • Total Symptom Score: A measure of the severity of symptoms experienced by patients with myeloproliferative neoplasms, used to assess quality of life and treatment effectiveness.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent increasing the dose or require a dose reduction.
  • VEXAS syndrome: A rare autoinflammatory condition characterized by blood abnormalities and systemic inflammation.